155 related articles for article (PubMed ID: 20195643)
1. New therapies, new concerns: rituximab-associated lung injury.
Lands LC
Pediatr Nephrol; 2010 Jun; 25(6):1001-3. PubMed ID: 20195643
[No Abstract] [Full Text] [Related]
2. [Cryptococcus neoformans meningoencephalitis in a patient treated with rituximab].
Sánchez-Ojanguren J; Isern-Segura I; Chico-Chumillas C; Javaloyas-de-Morlius M
Med Clin (Barc); 2009 Jun; 133(4):157-8. PubMed ID: 19268330
[No Abstract] [Full Text] [Related]
3. Organizing pneumonia associated with rituximab: Challenges raised by establishing causality.
Lioté H
Joint Bone Spine; 2008 May; 75(3):260-2. PubMed ID: 18424160
[No Abstract] [Full Text] [Related]
4. Late-onset neutropenia following rituximab.
McLaughlin P
Leuk Lymphoma; 2006 Jun; 47(6):965-6. PubMed ID: 16840184
[No Abstract] [Full Text] [Related]
5. The infectious consequences of rituximab addition to fludarabine-containing regimens.
Tam CS; Seymour JF
Blood; 2006 Apr; 107(7):3013-4. PubMed ID: 16554491
[No Abstract] [Full Text] [Related]
6. FDA: Increased HBV reactivation risk with ofatumumab or rituximab.
Mitka M
JAMA; 2013 Oct; 310(16):1664. PubMed ID: 24150447
[No Abstract] [Full Text] [Related]
7. Rituximab (B-cell depleting antibody) associated lung injury (RALI): a pediatric case and systematic review of the literature.
Bitzan M; Anselmo M; Carpineta L
Pediatr Pulmonol; 2009 Sep; 44(9):922-34. PubMed ID: 19681063
[TBL] [Abstract][Full Text] [Related]
8. Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy.
Korte W; Jost C; Cogliatti S; Hess U; Cerny T
Ann Oncol; 1999 Oct; 10(10):1249-50. PubMed ID: 10586345
[No Abstract] [Full Text] [Related]
9. Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma.
Otrock ZK; Hatoum HA; Salem ZM
Intern Emerg Med; 2008 Jun; 3(2):161-3. PubMed ID: 18270789
[No Abstract] [Full Text] [Related]
10. Fatal cytokine release syndrome with chimeric anti-CD20 monoclonal antibody rituximab in a 71-year-old patient with chronic lymphocytic leukemia.
Lim LC; Koh LP; Tan P
J Clin Oncol; 1999 Jun; 17(6):1962-3. PubMed ID: 10561242
[No Abstract] [Full Text] [Related]
11. Rituximab-induced vasculitis.
Dereure O; Navarro R; Rossi JF; Guilhou JJ
Dermatology; 2001; 203(1):83-4. PubMed ID: 11549810
[No Abstract] [Full Text] [Related]
12. Rituximab-related urticarial reaction in a patient treated for primary cutaneous B-cell lymphoma.
Errante D; Bernardi D; Bianco A; De Nardi S; Salvagno L
Ann Oncol; 2006 Nov; 17(11):1720-1. PubMed ID: 16731537
[No Abstract] [Full Text] [Related]
13. Chronic hepatitis after hepatitis E virus infection in a patient with non-Hodgkin lymphoma taking rituximab.
Ollier L; Tieulie N; Sanderson F; Heudier P; Giordanengo V; Fuzibet JG; Nicand E
Ann Intern Med; 2009 Mar; 150(6):430-1. PubMed ID: 19293084
[No Abstract] [Full Text] [Related]
14. Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy.
Westhoff TH; Jochimsen F; Schmittel A; Stoffler-Meilicke M; Schafer JH; Zidek W; Gerlich WH; Thiel E
Blood; 2003 Sep; 102(5):1930. PubMed ID: 12930732
[No Abstract] [Full Text] [Related]
15. Delayed-type hypersensitivity reaction or serum sickness after rituximab treatment.
Hellerstedt B; Ahmed A
Ann Oncol; 2003 Dec; 14(12):1792. PubMed ID: 14630688
[No Abstract] [Full Text] [Related]
16. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma.
Dillman RO
J Clin Oncol; 2002 Aug; 20(16):3545-57. PubMed ID: 12177115
[No Abstract] [Full Text] [Related]
17. Severe thrombocytopenia and clinical bleeding associated with rituximab infusion in a lymphoma patient with massive splenomegaly without leukemic invasion.
Rigamonti C; Volta C; Colombi S; Forti L; Savinelli F; Gaidano G; Bartoli E
Leukemia; 2001 Jan; 15(1):186-7. PubMed ID: 11243389
[No Abstract] [Full Text] [Related]
18. Rituximab-induced acute pulmonary fibrosis.
Leon RJ; Gonsalvo A; Salas R; Hidalgo NC
Mayo Clin Proc; 2004 Jul; 79(7):949, 953. PubMed ID: 15244399
[No Abstract] [Full Text] [Related]
19. Three cases of activation of cutaneous squamous-cell carcinoma during treatment with prolonged administration of rituximab.
Fogarty GB; Bayne M; Bedford P; Bond R; Kannourakis G
Clin Oncol (R Coll Radiol); 2006 Mar; 18(2):155-6. PubMed ID: 16523821
[No Abstract] [Full Text] [Related]
20. Does rituximab really induce hepatitis C virus reactivation?
Ennishi D; Yokoyama M; Terui Y; Takeuchi K; Ikeda K; Tanimoto M; Hatake K
J Clin Oncol; 2008 Oct; 26(28):4695-6; author reply 4696. PubMed ID: 18824720
[No Abstract] [Full Text] [Related]
[Next] [New Search]
